A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
基本信息
- 批准号:10045730
- 负责人:
- 金额:$ 24.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-08-15 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdverse eventAffectAgingAmericanAreaAttentionBeliefBenefits and RisksBiologicalBiometryCardiac OutputCardiologyCaringClinical TrialsCommunicationComplexCrossover DesignDataDevelopmentEFRACEffectivenessElderlyEnsureEnvironmentEventFailureFoundationsFundingFutureGeriatricsGoalsGrantHealthHealth PrioritiesHeartHeart failureImpairmentIndividualInterventionKnowledgeLeadLeftLife ExpectancyManuscriptsMedication ManagementMedicineMentorsMentorshipOffice VisitsOutcomeParticipantPatient Outcomes AssessmentsPatientsPersonal SatisfactionPharmaceutical PreparationsPolypharmacyPopulationPopulation StudyPositioning AttributePrincipal InvestigatorProcessProtocols documentationRandomized Controlled TrialsResearch PersonnelResearch Project GrantsRoleSignal TransductionSyndromeTestingTherapeuticTimeTrainingUncertaintyUnited StatesVariantVentricularaging populationbasecareercareer developmentclinical practicecollegedrug withdrawaleffectiveness implementation studyeffectiveness implementation trialexperienceexperimental studyhospitalization ratesimplementation scienceimprovedimproved outcomeindividual patientinnovationiterative designmortalitymultiple chronic conditionsnovelpatient orientedpreferencepreservationpreventprogramsprototypeshared decision makingskillssuccesssupportive environmenttheoriesworking group
项目摘要
PROJECT SUMMARY
Candidate: My career goal is to improve the wellbeing of older adults with multiple chronic conditions and
polypharmacy by developing and rigorously testing rational strategies to improve medication prescribing
practices; and to become an independent clinician investigator and national leader in Geriatric Cardiology. This
area is particularly relevant for me as a heart failure cardiologist, as I care for older adults who almost
universally have multiple chronic conditions and polypharmacy. My track record as an emerging leader in this
area is evidenced by multiple lead- and senior-author manuscripts, 4 grants as the Principal Investigator
including a GEMSSTAR, my position as the Founding Director of the Weill Cornell Heart Failure with
Preserved Ejection (HFpEF) Program for the Aging, and my role as the Chair of the American College of
Cardiology Geriatric Cardiology Section Early Career Professionals Working Group. Mentors and Environment:
This project will be conducted under the mentorship of 4 well-funded investigators who will contribute their
complementary expertise in Geriatrics (Mark Lachs), Geriatric Cardiology (Mathew Maurer),
Implementation Science (Monika Safford), and N-of-1 trials (Ian Kronish). Advisors in deprescribing, shared
decision making, and biostatistics will provide additional content expertise to ensure the success of the
proposed project and catalyze my career development. This project will take place within the supportive
environment of Weill Cornell Medicine, which has demonstrated a deep commitment to my development as a
clinician-investigator for the past several years. Mentored Research Project: Despite its role as an integral part
of patient-centric and goal-concordant prescribing practice, deprescribing is seldom incorporated into clinical
practice due to several barriers. To improve patient-centered medication management, there is a need to
develop processes that can overcome these barriers. The objective of this proposal is to determine whether N-
of-1 trials—as a pragmatic patient-centered approach to medication optimization that can overcome key
barriers of deprescribing— can lead to increased patient confidence regarding the decision to continue or
discontinue a medication. To achieve this, I will: 1) determine key features of a feasible and pragmatic protocol
for deprescribing N-of-1 trials using a stakeholder-engaged iterative design approach; and 2) determine the
preliminary effectiveness of an adapted N-of-1 protocol on patient decision confidence and deprescribing, and
3) determine the facilitators and barriers of implementing an adapted N-of-1 protocol into real-world clinical
practice by conducting a type-1 hybrid effectiveness-implementation trial. I will achieve these aims by using ß-
blocker in heart failure with preserved ejection fraction (HFpEF) as a prototype for older adults with
multimorbidity and polypharmacy. This proposal will inform a future multicenter randomized controlled trial
focused on improving patient-reported outcomes, and provide a formative opportunity for me to obtain the
knowledge and skills necessary to become a leading researcher on patient-centered medication management.
项目摘要
候选人:我的职业目标是改善患有多种慢性疾病的老年人的健康状况,
通过开发和严格测试合理的策略来改善药物处方,
实践;并成为一个独立的临床研究人员和老年心脏病的国家领导人。这
作为一名心力衰竭心脏病专家,这一领域与我特别相关,因为我照顾的老年人几乎
普遍有多种慢性疾病和多种药物。我作为这方面的新兴领导者的记录
多个主要作者和资深作者的手稿,作为主要研究者的4笔赠款,
包括一个GEMSSTAR,我作为威尔康奈尔心脏衰竭的创始主任的职位,
保留射血(HFpEF)计划的老龄化,以及我作为主席的美国大学的作用,
心脏病学老年心脏病学科早期职业专业人员工作组。导师与环境:
该项目将在4名资金充足的调查人员的指导下进行,他们将贡献他们的
老年医学(Mark Lachs),老年心脏病学(Mathew Maurer),
实施科学(Monika Safford)和N-of-1试验(Ian Kronish)。取消处方方面的顾问,共享
决策和生物统计学将提供额外的内容专业知识,以确保成功的
提出项目并促进我的职业发展。该项目将在支持性的
威尔康奈尔医学的环境,这表明了我作为一个发展的深刻承诺,
在过去的几年里,临床研究员。指导研究项目:尽管它的作用是一个不可分割的一部分
以病人为中心和目标一致的处方实践,取消处方很少被纳入临床
实践中遇到了一些障碍。为了改善以患者为中心的药物管理,需要
开发能够克服这些障碍的流程。本提案的目的是确定N-
作为一种务实的以患者为中心的药物优化方法,
取消处方的障碍-可能导致患者对继续或
停止服药。为了实现这一点,我将:1)确定一个可行的和务实的协议的关键特征
使用利益相关者参与的迭代设计方法取消N-of-1试验;以及2)确定
经调整的N-of-1方案对患者决策信心和取消处方的初步有效性,以及
3)确定在现实世界的临床中实施适应性N-of-1方案的促进因素和障碍
通过进行类型1混合有效性-实施试验来实践。我将通过使用这些工具来实现这些目标-
左室射血分数正常的心力衰竭阻滞剂(HFpEF)作为老年人的原型,
多药治疗和多药治疗。该建议将为未来的多中心随机对照试验提供信息
专注于改善患者报告的结果,并为我提供一个形成的机会,以获得
成为以患者为中心的药物管理的领先研究人员所需的知识和技能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PARAG GOYAL其他文献
PARAG GOYAL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PARAG GOYAL', 18)}}的其他基金
Advancing the Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention
推进对话有助于提高疾病轨迹 (CHAT) 干预意识
- 批准号:
10668058 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10227996 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10433979 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别:
A Novel Deprescribing Intervention for Heart Failure with Preserved Ejection Fraction (HFpEF): A Prototype for Older Adults with Multimorbidity and Polypharmacy
射血分数保留 (HFpEF) 心力衰竭的新型处方干预措施:针对患有多种疾病和多药治疗的老年人的原型
- 批准号:
10673696 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 24.3万 - 项目类别: